<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Infectious%20Diseases/Urinary%20Tract%20Infections/">
    <link rel="shortcut icon" href="../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Urinary Tract Infections - MedNotes</title>
    <link href="../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../js/jquery-3.2.1.min.js"></script>
    <script src="../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Urinary Tract Infections", url: "#_top", children: [
          ]},
          {title: "Diagnosis \u0026amp; Workup", url: "#diagnosis-workup", children: [
          ]},
          {title: "Principles of Management", url: "#principles-of-management", children: [
          ]},
          {title: "Uncomplicated Cystitis", url: "#uncomplicated-cystitis", children: [
          ]},
          {title: "Pyelonephritis", url: "#pyelonephritis", children: [
          ]},
          {title: "UTI in Pregnant Women", url: "#uti-in-pregnant-women", children: [
          ]},
          {title: "Prevention of UTI", url: "#prevention-of-uti", children: [
          ]},
        ];

    </script>
    <script src="../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Antibiotics/Cephalosporins/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Antibiotics/Cephalosporins/" class="btn btn-xs btn-link">
        Cephalosporins
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Tick%20Borne%20Infections/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Tick%20Borne%20Infections/" class="btn btn-xs btn-link">
        Tick-Borne Infections
      </a>
    </div>
    
  </div>

    

    <h1 id="urinary-tract-infections">Urinary Tract Infections</h1>
<p>Acute uncomplicated UTI:</p>
<ul>
<li>
<p>E coli (75-90%)</p>
</li>
<li>
<p>Staphylococcus saprophyticus (5-15%)</p>
<ul>
<li>Especially in young, sexually active women</li>
</ul>
</li>
<li>
<p>Klebsiella</p>
</li>
<li>
<p>Proteus mirabilis</p>
</li>
<li>
<p>Citrobacter</p>
</li>
<li>
<p>Enterococcus</p>
</li>
</ul>
<p>Complicated UTI:</p>
<ul>
<li>
<p>Same as above, but also:</p>
</li>
<li>
<p>Pseudomonas</p>
</li>
<li>
<p>Acinetobacter</p>
</li>
<li>
<p>Morganella</p>
</li>
<li>
<p>Staphylococcus</p>
</li>
<li>
<p>Yeast</p>
</li>
</ul>
<table><thead><tr class="header"><th>Â </th><th><strong>Outpatients</strong></th><th><strong>Inpatients</strong></th></tr></thead><tbody><tr class="odd"><td><em>Escherichia coli</em></td><td>75%</td><td>Common</td></tr><tr class="even"><td><em>Klebsiella</em></td><td>15%</td><td>Common</td></tr><tr class="odd"><td><em>Proteus</em></td><td>5%</td><td>Common</td></tr><tr class="even"><td>Enterococci</td><td>2%</td><td>Common</td></tr><tr class="odd"><td><em>Staphylococcus epidermidis</em></td><td>&lt;2%</td><td>Common</td></tr><tr class="even"><td>Group B streptococci</td><td>&lt;2%</td><td>Common</td></tr><tr class="odd"><td><em>Pseudomonas</em></td><td>Rare</td><td>Common</td></tr></tbody></table>

<ul>
<li>In 95% of cases, UTIs are monomicrobial</li>
</ul>
<h1 id="diagnosis-workup">Diagnosis &amp; Workup</h1>
<ul>
<li>
<p><strong>Urinalysis</strong> should be performed for all patients with possible UTI</p>
<ul>
<li>
<p>&gt;10 WBC/HPF indicates pyuria</p>
</li>
<li>
<p>Leukocyte esterase dipstick is generally sensitive, but can have false negs</p>
</li>
<li>
<p>WBC casts is strong evidence for pyelonephritis</p>
</li>
<li>
<p>Increased protein is common as well</p>
</li>
</ul>
</li>
<li>
<p><strong>Urine culture</strong> allows for quantitation to differentiate contamination (usual) from active infection</p>
<ul>
<li>
<p>Not required in sexually active women with early cystitis</p>
</li>
<li>
<p>More than 10<sup>5</sup> organisms per mL indicates infection, but sympatomatic women can have as few as 10<sup>3</sup> per mL</p>
</li>
<li>
<p><u>The IDSA recommends &gt;10<sup>3</sup> per mL as an indication of infection in symptomatic patients</u></p>
</li>
<li>
<p>Follow-up with repeat culture if symptoms relapse</p>
</li>
</ul>
</li>
<li>
<p><strong>Ultrasound</strong> to image:</p>
<ul>
<li>
<p>Patients with upper tract disease, and persistent fever, on antibiotics</p>
</li>
<li>
<p>Preschool girls with second UTI</p>
</li>
<li>
<p>Any male with UTI</p>
</li>
</ul>
</li>
<li>
<p><strong>IV pyelogram</strong> to work up anatomic obstruction, but avoid in MM or AKI</p>
</li>
<li>
<p><strong>CT abdomen</strong> for perinephric abscess, anatomic defects, obstruction, calculi, etc</p>
</li>
</ul>
<h1 id="principles-of-management">Principles of Management</h1>
<h1 id="uncomplicated-cystitis">Uncomplicated Cystitis</h1>
<ul>
<li>
<p>Background:</p>
<ul>
<li>
<p>Should be treated if symptomatic, and pregnant women should have all ASB treated as well</p>
</li>
<li>
<p>Most can be treated over the phone, without physical examiantion</p>
</li>
<li>
<p>TMP-SMX used to be the first line therapy in 1999, but now there is no single best agent</p>
</li>
</ul>
</li>
<li>
<p><strong>Antibiotic Regimens</strong></p>
<ul>
<li>
<p><u>First-Line</u></p>
<ul>
<li>
<p><em>TMP-SMX</em></p>
<ul>
<li>
<p>Dose: 1 double strength tablet BID for 3 days</p>
</li>
<li>
<p>Increasing resistance, consider if local resistance &lt;20%</p>
</li>
</ul>
</li>
<li>
<p><em>Nitrofurantoin</em></p>
<ul>
<li>
<p>Dose: 100 mg bid for 5-7 days</p>
</li>
<li>
<p>Resistance remains fairly low</p>
</li>
<li>
<p>Highly active against E coli and most non-E coli isolates</p>
</li>
<li>
<p>Proteus, Pseudomonas, Serratia, Enterobacter, and yeast are intrinsically resistant</p>
</li>
<li>
<p>Do NOT use to treat pyelonephritis, does not reach therapeutic levels in the tissue</p>
</li>
</ul>
</li>
<li>
<p><em>Fosfomycin</em></p>
<ul>
<li>
<p>Retains activity against a majority of uropathogens that produce extended spectrum beta-lactamases</p>
</li>
<li>
<p>Single 3 gram dose</p>
</li>
<li>
<p>This is less effective than a 5 day course of nitrofurantoin</p>
</li>
</ul>
</li>
<li>
<p><em>Pivmecillinam</em></p>
<ul>
<li>May not be available in Canada</li>
</ul>
</li>
</ul>
</li>
<li>
<p><u>Second-Line</u></p>
<ul>
<li>
<p><em>Fluoroquinolones</em></p>
<ul>
<li>
<p>Highly effective (cipro or levo), except for moxi (low urinary levels)</p>
</li>
<li>
<p>Issues:</p>
<ul>
<li>
<p>Resistance</p>
</li>
<li>
<p>Side effects</p>
<ul>
<li>
<p>Achilles tendinopathy</p>
</li>
<li>
<p>Irreversible neuropathy</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Therefore, use when other choices are not reasonable</p>
</li>
</ul>
</li>
<li>
<p><em>Beta-lactams</em></p>
<ul>
<li>
<p>Less effective; fail to eliminate uropathogens from the vaginal reservoir</p>
</li>
<li>
<p>Many strains of E coli that are resistant to TMP-SMX are also resistant to amoxicillin and cephalexin</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><u>Duration of Therapy</u></p>
<ul>
<li>Avoid short course (5 days) of therapy in men, upper tract symptoms, women with symptoms more than a week in duration, diabetics</li>
</ul>
</li>
</ul>
</li>
</ul>
<h1 id="pyelonephritis">Pyelonephritis</h1>
<ul>
<li>
<p>Background:</p>
<ul>
<li>
<p>Tissue-invasive disease</p>
</li>
<li>
<p>Treatment needs to work, and needs to reach therapeutic levels very quickly</p>
</li>
<li>
<p>There are high rates of TMP-SMX resistant E coli in patients with pyelonephritis</p>
</li>
<li>
<p>Requires a longer duration of therapy</p>
</li>
<li>
<p>Uncomplicated</p>
</li>
<li>
<p>responds to 7 days well, otherwise 14 days is reasonable</p>
</li>
</ul>
</li>
<li>
<p><strong>Antibiotic Regimens</strong></p>
<ul>
<li>
<p><u>First-Line</u></p>
<ul>
<li>
<p><em>Fluoroquinolones</em></p>
<ul>
<li>
<p>PO or IV are bioequivalent</p>
</li>
<li>
<p>7-day course is highly effective for initial management in the outpatient setting</p>
</li>
<li>
<p><em>Preferred for empiric therapy</em></p>
</li>
</ul>
</li>
<li>
<p><em>TMP-SMX</em></p>
<ul>
<li>
<p>PO x 14 days is effective for uncomplicated pyelonephritis if the pathogen is known to be susceptible</p>
</li>
<li>
<p>If the susceptibility is unknown, use with an initial dose of ceftriaxone 1 gram IV</p>
</li>
</ul>
</li>
<li>
<p><em>Amox-clav</em></p>
</li>
</ul>
</li>
<li>
<p><u>Parenteral (more serious disease)</u></p>
<ul>
<li>
<p>Fluoroquinolones</p>
</li>
<li>
<p>Extended spectrum cephalosporin +/- aminoglycoside</p>
<ul>
<li><em>IV ceftriaxone, if there is no history of MDR pathogen or recent hospitalizations</em></li>
</ul>
</li>
<li>
<p>Carbapenem</p>
</li>
<li>
<p><em>Once there is clinical response, should switch to oral from parenteral</em></p>
</li>
</ul>
</li>
<li>
<p><u>Higher-Risk Patients</u></p>
<ul>
<li>
<p>Beta-lactam + beta-lactamase-inhibitor</p>
<ul>
<li><em>Pip-tazo (pseudomonas)</em></li>
</ul>
</li>
<li>
<p><em>Cefepime (pseudomonas coverage)</em></p>
</li>
<li>
<p>Carbapenem</p>
<ul>
<li>ESBL</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Consider previous urine cultures to guide initial empiric coverage</p>
</li>
</ul>
</li>
</ul>
<h1 id="uti-in-pregnant-women">UTI in Pregnant Women</h1>
<ul>
<li>
<p><strong>Nitrofurantoin, ampicillin, and cephalosporins are relatively safe in early pregnancy</strong></p>
</li>
<li>
<p>Pregnant women with overt pyelonephritis should get parenteral beta-lactam +/- aminoglycoside</p>
</li>
<li>
<p>AVOID:</p>
<ul>
<li>
<p>Sulfonamides</p>
</li>
<li>
<p>Fluoroquinolones</p>
</li>
</ul>
</li>
</ul>
<h1 id="prevention-of-uti">Prevention of UTI</h1>
<ul>
<li>
<p><strong>Sexually active women:</strong></p>
<ul>
<li>
<p>Void after sex</p>
</li>
<li>
<p>Single-dose TMP-SMX after sex</p>
</li>
</ul>
</li>
<li>
<p><strong>Anatomic defects and children:</strong></p>
<ul>
<li>Daily low dose (1/2 tab) TMP-SMX daily, or 50 mg nitrofurantoin daily</li>
</ul>
</li>
<li>
<p><strong>Indwelling catheters:</strong></p>
<ul>
<li>
<p>Abx ppx is not effective, and selects for antibiotic-resistant pathogens</p>
</li>
<li>
<p>Remove catheters ASAP</p>
</li>
</ul>
</li>
</ul>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Antibiotics/Cephalosporins/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Antibiotics/Cephalosporins/" class="btn btn-xs btn-link">
        Cephalosporins
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Tick%20Borne%20Infections/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Tick%20Borne%20Infections/" class="btn btn-xs btn-link">
        Tick-Borne Infections
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>